GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences: No Deviation in Rights Issue Fund Utilization for Q3 2026
FUNDRAISE ● No Immediate Change LOW RISK
📅 Filed on BSE: 16 Oct 2026, 04:03 PM IST  ·  BSE ID: 2ce14829-819a-48e2-86e3-f31c886d4dba
View Original BSE Filing (PDF)
💡
In Simple Terms
The company used money from its recent share offering as planned and informed the stock exchanges.
🤖 AI Summary
  • Solara Active Pharma Sciences reports no deviation in Rights Issue fund utilization for Q3 2026.
  • Rs. 446.62 Crores raised via Rights Issue, with Rs. 334.71 Crores for debt repayment.
  • Rs. 111.57 Crores allocated for general corporate purposes, within limits.
  • Statement reviewed and noted by the company's Audit Committee on October 16, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Amount Raised (In crores)
Rs. 446.62 Crores
Funds Utilised for Repayment or Pre-payment of Borrowings
Rs. 334.71 Crores
Funds Utilised for General Corporate Purpose
Rs. 105.17 Crores
🏢 How This Affects the Company
💰
Financial Impact
The filing confirms adherence to the planned allocation of funds raised through the Rights Issue, indicating stability in financial management concerning debt reduction and operational funding.
⚠️
Risk Impact
This disclosure mitigates potential investor concerns regarding the prudent use of capital raised, reinforcing compliance with regulatory requirements.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders regarding this disclosure.
👤
Who Is Affected
All shareholders are affected by the confirmation of compliant fund utilization, reinforcing transparency.
🔍
Management Signal
Management signals adherence to the stated objectives of the Rights Issue and transparent financial reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Next quarterly results for updated financial performance.
Future disclosures on Rights Issue fund utilization.
Monitoring of debt levels and general corporate expense trends.
LOW RISK The filing confirms no deviation in fund utilization, reducing associated financial and regulatory risks.
💡 Investor Takeaway
Solara Active Pharma Sciences confirms no deviation in Rights Issue fund use for Q3 2026. Rs. 446.62 Crores raised, with Rs. 334.71 Crores for debt repayment and Rs. 111.57 Crores for general corporate purposes.
⚖️ Strengths & Concerns

✅ Positives

  • No deviation in fund utilization confirms disciplined financial execution as per the Rights Issue plan.
  • Utilization of Rs. 334.71 Crores for debt repayment directly addresses outstanding borrowings as planned.
❓ Frequently Asked Questions
What is the total amount raised by Solara Active Pharma Sciences through its Rights Issue?
Solara Active Pharma Sciences raised Rs. 446.62 Crores through its Rights Issue.
How were the funds from Solara Active Pharma Sciences' Rights Issue utilized in Q3 2026?
Rs. 334.71 Crores were used for debt repayment, and Rs. 105.17 Crores for general corporate purposes.
Was there any deviation in the utilization of funds raised by Solara Active Pharma Sciences for the quarter ended September 30, 2026?
No, Solara Active Pharma Sciences reported no deviation or variation in the utilization of funds for the quarter ended September 30, 2026.
Which committee reviewed the statement of deviation/variation for Solara Active Pharma Sciences' Rights Issue proceeds?
The statement of deviation/variation was placed before and noted by the Audit Committee of Solara Active Pharma Sciences.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.